191 related articles for article (PubMed ID: 25596342)
21. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
Djelti F; Braudeau J; Hudry E; Dhenain M; Varin J; Bièche I; Marquer C; Chali F; Ayciriex S; Auzeil N; Alves S; Langui D; Potier MC; Laprevote O; Vidaud M; Duyckaerts C; Miles R; Aubourg P; Cartier N
Brain; 2015 Aug; 138(Pt 8):2383-98. PubMed ID: 26141492
[TBL] [Abstract][Full Text] [Related]
22. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.
Valenza M; Chen JY; Di Paolo E; Ruozi B; Belletti D; Ferrari Bardile C; Leoni V; Caccia C; Brilli E; Di Donato S; Boido MM; Vercelli A; Vandelli MA; Forni F; Cepeda C; Levine MS; Tosi G; Cattaneo E
EMBO Mol Med; 2015 Dec; 7(12):1547-64. PubMed ID: 26589247
[TBL] [Abstract][Full Text] [Related]
23. Huntingtin functions as a scaffold for selective macroautophagy.
Rui YN; Xu Z; Patel B; Chen Z; Chen D; Tito A; David G; Sun Y; Stimming EF; Bellen HJ; Cuervo AM; Zhang S
Nat Cell Biol; 2015 Mar; 17(3):262-75. PubMed ID: 25686248
[TBL] [Abstract][Full Text] [Related]
24. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance.
Warrier M; Shih DM; Burrows AC; Ferguson D; Gromovsky AD; Brown AL; Marshall S; McDaniel A; Schugar RC; Wang Z; Sacks J; Rong X; Vallim TA; Chou J; Ivanova PT; Myers DS; Brown HA; Lee RG; Crooke RM; Graham MJ; Liu X; Parini P; Tontonoz P; Lusis AJ; Hazen SL; Temel RE; Brown JM
Cell Rep; 2015 Jan; 10(3):326-338. PubMed ID: 25600868
[TBL] [Abstract][Full Text] [Related]
25. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
26. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.
Sturrock A; Laule C; Wyper K; Milner RA; Decolongon J; Dar Santos R; Coleman AJ; Carter K; Creighton S; Bechtel N; Bohlen S; Reilmann R; Johnson HJ; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
Mov Disord; 2015 Mar; 30(3):393-401. PubMed ID: 25690257
[TBL] [Abstract][Full Text] [Related]
27. Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.
Wolf RC; Thomann PA; Sambataro F; Wolf ND; Vasic N; Landwehrmeyer GB; Süßmuth SD; Orth M
J Neurol; 2015; 262(4):859-69. PubMed ID: 25626721
[TBL] [Abstract][Full Text] [Related]
28. Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy.
Sasazawa Y; Sato N; Umezawa K; Simizu S
J Biol Chem; 2015 Mar; 290(10):6168-78. PubMed ID: 25596530
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial quality control: Easy come, easy go.
Stotland A; Gottlieb RA
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt B):2802-11. PubMed ID: 25596427
[TBL] [Abstract][Full Text] [Related]
30. Huntington's disease: looking beyond the movement disorder.
Morreale MK
Adv Psychosom Med; 2015; 34():135-42. PubMed ID: 25832519
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
[TBL] [Abstract][Full Text] [Related]
32. Untargeted metabolic profiling identifies interactions between Huntington's disease and neuronal manganese status.
Kumar KK; Goodwin CR; Uhouse MA; Bornhorst J; Schwerdtle T; Aschner M; McLean JA; Bowman AB
Metallomics; 2015 Feb; 7(2):363-70. PubMed ID: 25599126
[TBL] [Abstract][Full Text] [Related]
33. The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
Arndt JR; Chaibva M; Legleiter J
Biomol Concepts; 2015 Mar; 6(1):33-46. PubMed ID: 25741791
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders.
Mena NP; Urrutia PJ; Lourido F; Carrasco CM; Núñez MT
Mitochondrion; 2015 Mar; 21():92-105. PubMed ID: 25667951
[TBL] [Abstract][Full Text] [Related]
35. The diversity of GABA(A) receptor subunit distribution in the normal and Huntington's disease human brain.
Waldvogel HJ; Faull RL
Adv Pharmacol; 2015; 73():223-64. PubMed ID: 25637443
[TBL] [Abstract][Full Text] [Related]
36. Da-bu-yin-wan and qian-zheng-san to neuroprotect the mouse model of Parkinson's disease.
Gong XG; Sun HM; Zhang Y; Zhang SJ; Gao YS; Feng J; Hu JH; Gai C; Guo ZY; Xu H; Ma L
Evid Based Complement Alternat Med; 2014; 2014():729195. PubMed ID: 25610480
[TBL] [Abstract][Full Text] [Related]
37. Treating the whole body in Huntington's disease.
Carroll JB; Bates GP; Steffan J; Saft C; Tabrizi SJ
Lancet Neurol; 2015 Nov; 14(11):1135-42. PubMed ID: 26466780
[TBL] [Abstract][Full Text] [Related]
38. Recent advances and applications of metabolomics to investigate neurodegenerative diseases.
Ibáñez C; Cifuentes A; Simó C
Int Rev Neurobiol; 2015; 122():95-132. PubMed ID: 26358892
[TBL] [Abstract][Full Text] [Related]
39. Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.
Laprairie RB; Bagher AM; Precious SV; Denovan-Wright EM
Pharmacol Res Perspect; 2015 Feb; 3(1):e00104. PubMed ID: 25692022
[TBL] [Abstract][Full Text] [Related]
40. Short-interval observational data to inform clinical trial design in Huntington's disease.
Hobbs NZ; Farmer RE; Rees EM; Cole JH; Haider S; Malone IB; Sprengelmeyer R; Johnson H; Mueller HP; Sussmuth SD; Roos RA; Durr A; Frost C; Scahill RI; Landwehrmeyer B; Tabrizi SJ
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1291-8. PubMed ID: 25669748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
